Arvinas Shares Outstanding 2017-2021 | ARVN

Arvinas shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Arvinas Annual Shares Outstanding
(Millions of Shares)
2020 40
2019 33
2018 9
2017 2
2016 2
Arvinas Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 49
2021-03-31 49
2020-12-31 40
2020-09-30 39
2020-06-30 39
2020-03-31 39
2019-12-31 33
2019-09-30 33
2019-06-30 31
2019-03-31 31
2018-12-31 9
2018-09-30 2
2018-06-30 2
2018-03-31 2
2017-12-31
2017-09-30 2
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.334B $0.022B
Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57